This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
DigitalHealth Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
Recently, the company launched Medable AI and Medable Studio to automatically convert outcomes assessments into fully digital eCOAs in seconds now accessible on Google Cloud Marketplace. Medable will also be presenting with Christina Fawcet , Director of DigitalHealth Delivery at GSK, on Wednesday, Feb. 5 at 9:55am.
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of DrugDevelopment (CSDD)s PACT Consortium links decentralized clinical trial (DCT) approaches to notably higher participation rates across multiple demographic groups. 5 at 9:55am.
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Koneksa’s innovative digital model aims to address limitations in existing functional status assessments by leveraging digitalhealth technologies (DHTs) for both objective and self-reported outcomes. Chief Medical Officer, Koneksa. Chief Scientific Officer, Koneksa.
That doesn’t just lead to faster trials, it changes the way companies can think about drugdevelopment going from waterfall big bets to agile research.” . “We’re fixing that with a new paradigm for running trials underpinned by technology.
–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digitalhealth solutions to better meet the needs of healthcare professionals, regulators and patients. in 2060.
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drugdevelopment, drug manufacturing and digitalhealth investment.
As these implementations take hold, the emphasis will be on demonstrating measurable return on investment (ROI), with AI driving down administrative burdens, accelerating drugdevelopment, and significantly improving operational efficiency. What’s most exciting to me is AI’s potential impact on personalized medicine.
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
A Tufts Center for the Study of DrugDevelopment study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively. Medable, which ranked in the top 8% of software companies on the 2023 Inc.
David Slifka, Vice President, Commercial Enablement The digitalhealth ecosystem is a complex place. Confusion abounds among healthcare providers regarding digital therapeutics (DTx) terminology and classifications, and understandably so. DTx fall within the digital medicine subset within the larger digitalhealth ecosystem.
A Tufts Center for the Study of DrugDevelopment study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M
A Tufts Center for the Study of DrugDevelopment study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M
1 The collaboration between Massive Bio and Mika Health will also benefit the research both companies are performing with pharmaceutical companies and patient advocacy groups, by providing real-world data and insights into patient experiences and treatment outcomes.
“Avilar is pioneering the next frontier in protein degradation and we are excited that our significant progress over the past year in discovering and advancing extracellular protein degraders has attracted this group of leading investors,” said Daniel Grau, CEO and President of Avilar Therapeutics. Find out more: www.sanofiventures.com.
With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies.” ClavystBio was conceived and launched by Temasek to be a venture builder, trusted partner, and keystone to catalyze global health solutions from Singapore.
A Tufts Center for the Study of DrugDevelopment study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment of on average of $500K in Phase 2 and $1.5M in Phase 3.
Engage with Stakeholders: Actively engage with NHS staff, patients, and advocacy groups to understand their concerns and address them proactively. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk Subscribe Today!
It can be used to create new drugs, develop personalized treatment plans, and even generate synthetic medical data. HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis. But how can healthcare organisations best leverage this technology? Subscribe Today!
DTx could be used in phase II of clinical trials for monitoring patients, helping reduce costs of drugdevelopment and speeding up that phase. Healthcare professionals are a very important group to adopt DTx but education is essential for them to understand the benefits and how to use DTx. What should be the best market access?
We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. The pipeline for new antibiotics is limited, which is partly due to how new drugdevelopment is funded.
Bardy Diagnostics is a digitalhealth and remote patient monitoring company focused on addressing a long-standing complaint by cardiac electrophysiologists and cardiologists regarding their frequent inability to clearly distinguish the P-wave on ECG strips of existing monitors. And the list will continue to be updated over time.
With access to these collective resources and by capitalizing on existing biosamples as well as clinical data, including that from digitalhealth technology, researchers will focus on identifying and validating biomarkers and therapeutic targets specific to ALS.
The industry is working to optimize information and data transfer between these groups, aiming to reduce redundancy and minimize manual processes that can introduce risks, whilst also generating process and product insights through technologies such as AI.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content